🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I like the sound of this man. I like his spirit of enterprise. The world needds more like him. bit.ly/3bxJ3Gr

Reflecting on the fact that Blofeld's base in DIAMONDS ARE FOREVER had an "If in doubt, ASK" sign posted in the control room. So few megalomaniacs get this! Whether your base is an oil rig or a volcano, empowering your minions via an atmosphere of mature inquiry is so important.

Happy to report that our paper on a new and highly reactive Click-to-Release reaction is now out in J. Am. Chem. Soc.. Great collaboration between Tagworks Pharmaceuticals and SyMO-Chem, Syncom, TU Eindhoven, Avipep and Levena. pubs.acs.org/doi/abs/10.102…

We have an exciting opportunity for a synthetic chemist to contribute to development of new cancer therapies based on Tagworks’ Click-to-Release platform tagworkspharma.com/company/career…

Check out this overview of bioorthogonal chemistry. Thanks to Joe Fox and Sam Scinto Fox Lab at UD for leading the charge !

We have an exciting opportunity for a synthetic chemist to contribute to the development of new cancer therapies based on Tagworks’ Click-to-Release platform tagworkspharma.com/company/career…

Meet our speakers: Marc Robillard. Cleavable Radioimmunoimaging to increase tumour-to-blood ratio. biorxiv.org/content/10.110… DYNAFLUORS BOOMchemistry.com Tagworks Pharmaceuticals @RSC_CBBG

We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics ! tagworkspharma.com/tagworks-pharm…

Het Nederlandse Tagworks Pharmaceuticals heeft een grote investeringsronde met succes afgesloten. De financiële impuls biedt het bedrijf de middelen om klinische studies met de belangrijkste kandidaat-ADC in gang te zetten: sciencelink.net/nieuws/tagwork…

‘Clicked’ drugs: researchers prove the remarkable chemistry in humans Featuring Tagworks Pharmaceuticals #portfolio nature.com/articles/s4158…

A concise synthetic approach to highly reactive click-to-release trans-cyclooctene linkers (Robillard et al. Tagworks Pharmaceuticals) …mistry-europe.onlinelibrary.wiley.com/doi/10.1002/ch…

Proud to have won the second place for this years LSX Lifestars Awards - Series A of the Year. Great recognition for Tagworks Pharmaceuticals and our fantastic group of investors ! Congrats to Complement Tx and Adcendo and thanks to European Lifestars Awards for this great night out !

We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. prnewswire.com/news-releases/…

We look forward to attending #AACR2025! We will share preclinical data that demonstrate the potential of our pioneering Click-to-Release platform to improve the standard of care for patients with #solidtumor #cancers. Learn more: bit.ly/41HXGDZ #ADCs #oncology

We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: bit.ly/4jrAErw

We’re excited to welcome Keith Orford, MD, PhD, as our new CMO! His leadership in #oncology research and clinical drug development will be invaluable as we transition to the clinic. Learn more: bit.ly/4jlSuw3

At #AACR2025, we presented preclinical data on the potential of our Click-to-Release treatment platform to enable safe, tolerable, and potent delivery of therapeutic candidates for #solidtumors. View the posters: bit.ly/4cM7yjT #ADCs #oncology

We’re proud to be featured in a #NatureBiotechnology profile on #radiopharmaceuticals! Our Click-to-Release treatment platform shows potential to remove dose-limiting toxicities to more safely and effectively treat #solidtumors. Read here: bit.ly/4mFOoB1

We’re innovating for patients with #solidtumors so they can have safer, more effective therapies. Developed with our pioneering Click-to-Release approach, our lead #oncology #ADC program called TGW101 is now recruiting for a #clinicaltrial. Learn more: bit.ly/44ykreP